-
Something wrong with this record ?
Linoleic Acid Alleviates Lipopolysaccharide Induced Acute Liver Injury via Activation of Nrf2
Q. Zhang, Y. Jiang, Y. Qin, J. Liu, Y. Xie, L. Zhang, K. Li, X. Wang, G. Liu
Status minimal Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- NF-E2-Related Factor 2 * metabolism MeSH
- Liver drug effects metabolism pathology MeSH
- Linoleic Acid * pharmacology MeSH
- Chemical and Drug Induced Liver Injury * metabolism drug therapy pathology prevention & control MeSH
- Lipopolysaccharides * toxicity MeSH
- Mice MeSH
- Oxidative Stress drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Linoleic acid (LA) not only functions as an essential nutrient, but also profoundly modulates oxidative stress and inflammatory response. However, the potential mechanisms have not been adequately researched. Hence, this study examined the potential pharmacological roles of LA and the underlying mechanisms in mice with lipopolysaccharide (LPS)-associated acute liver injury (ALI). The results indicated that treatment with LA alleviated the histopathological abnormalities in the hepatic and plasma levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutathione-S-transferase (GST) in mice with LPS exposure. In addition, LA inhibited the LPS-associated generation of proinflammatory factors, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and downregulated the hepatic myeloperoxidase (MPO) level. In addition, the administration of LA resulted in a reduction in hepatic malondialdehyde (MDA) levels and an elevation in liver superoxide dismutase (SOD), reduced glutathione (GSH), catalase (CAT), and glutathione peroxidase (GSH-PX) levels. Further investigations revealed that LA promoted the expression of nuclear factor E2-related factor (Nrf2) and NAD(P)H: quinone oxidoreductase 1 (NQO1). In addition, the beneficial outcomes of LA on LPS-induced acute liver failure were revered when Nrf2 was pharmacologically suppressed by ML385. These experimental results demonstrated that LA supplementation attenuated LPS-associated acute hepatic impairment in mice via the activation of Nrf2.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24015636
- 003
- CZ-PrNML
- 005
- 20250819152056.0
- 007
- ta
- 008
- 240820s2024 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935201 $2 doi
- 035 __
- $a (PubMed)39027955
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Zhang, Q. $u Department of Emergency and Critical Care Medicine, University-Town Hospital of Chongqing Medical University, Chongqing, China. lg@cqmu.edu.cn
- 245 10
- $a Linoleic Acid Alleviates Lipopolysaccharide Induced Acute Liver Injury via Activation of Nrf2 / $c Q. Zhang, Y. Jiang, Y. Qin, J. Liu, Y. Xie, L. Zhang, K. Li, X. Wang, G. Liu
- 520 9_
- $a Linoleic acid (LA) not only functions as an essential nutrient, but also profoundly modulates oxidative stress and inflammatory response. However, the potential mechanisms have not been adequately researched. Hence, this study examined the potential pharmacological roles of LA and the underlying mechanisms in mice with lipopolysaccharide (LPS)-associated acute liver injury (ALI). The results indicated that treatment with LA alleviated the histopathological abnormalities in the hepatic and plasma levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutathione-S-transferase (GST) in mice with LPS exposure. In addition, LA inhibited the LPS-associated generation of proinflammatory factors, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and downregulated the hepatic myeloperoxidase (MPO) level. In addition, the administration of LA resulted in a reduction in hepatic malondialdehyde (MDA) levels and an elevation in liver superoxide dismutase (SOD), reduced glutathione (GSH), catalase (CAT), and glutathione peroxidase (GSH-PX) levels. Further investigations revealed that LA promoted the expression of nuclear factor E2-related factor (Nrf2) and NAD(P)H: quinone oxidoreductase 1 (NQO1). In addition, the beneficial outcomes of LA on LPS-induced acute liver failure were revered when Nrf2 was pharmacologically suppressed by ML385. These experimental results demonstrated that LA supplementation attenuated LPS-associated acute hepatic impairment in mice via the activation of Nrf2.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a lipopolysacharidy $x toxicita $7 D008070
- 650 12
- $a faktor 2 související s NF-E2 $x metabolismus $7 D051267
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 12
- $a kyselina linolová $x farmakologie $7 D019787
- 650 12
- $a lékové postižení jater $x metabolismus $x farmakoterapie $x patologie $x prevence a kontrola $7 D056486
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a játra $x účinky léků $x metabolismus $x patologie $7 D008099
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jiang, Y.
- 700 1_
- $a Qin, Y.
- 700 1_
- $a Liu, J.
- 700 1_
- $a Xie, Y.
- 700 1_
- $a Zhang, L.
- 700 1_
- $a Li, K.
- 700 1_
- $a Wang, X.
- 700 1_
- $a Liu, G.
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, č. 3 (2024), s. 381-391
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39027955 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y - $z 0
- 990 __
- $a 20240820 $b ABA008
- 991 __
- $a 20250819152039 $b ABA008
- 999 __
- $a min $b bmc $g 2283503 $s 1227539
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c 3 $d 381-391 $e 20240717 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $b NLK116 $a Pubmed-20240820